UBX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
UBX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Unity Biotechnology has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.
Unity Biotechnology has No Moat: Unity Biotechnology operates in a highly competitive biotech sector with no significant market share, intellectual property, or cost advantages, resulting in a very weak competitive position.
Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.
The company's Moat Score is based on these criteria:
1. Market leadership and sustainable market shareBased on the research, GuruFocus believes Unity Biotechnology might have No Moat - Very weak/transient advantages.
For the Biotechnology subindustry, Unity Biotechnology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Unity Biotechnology's Moat Score distribution charts can be found below:
* The bar in red indicates where Unity Biotechnology's Moat Score falls into.
Unity Biotechnology (NAS:UBX) Moat Score Explanation
The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:
Moat Score | Moat Level |
10 | Wide Moat - Exceptionally dominant and durable wide moat |
8 - 9 | Wide Moat - Clear and robust wide moat |
7 | Wide Moat - Entry-level wide moat, clearly possessing durable advantages |
6 | Narrow Moat - Strong narrow moat, clearly distinguishable but not wide |
5 | Narrow Moat - Solid narrow moat |
4 | Narrow Moat - Discernible but modest moat |
1 - 3 | No Moat - Very weak/transient advantages |
0 | No Moat - No discernible moat |
Thank you for viewing the detailed overview of Unity Biotechnology's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander Hieu Nguyen | officer: See Remarks | C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Anirvan Ghosh | director, officer: Chief Executive Officer | C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Lynne Marie Sullivan | officer: See Remarks | C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Jamie Dananberg | officer: Chief Medical Officer | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Michael P. Samar | director | C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032 |
Nathaniel E David | director, officer: President | C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301 |
Gilmore Neil O'neill | director | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Alexander Azoy | officer: See Remarks | 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362 |
Graham K Cooper | director | C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Robert Nelsen | director | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
David L. Lacey | director | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kristina Burow | director | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Camille D Samuels | director | 2463 JACKSON ST., SAN FRANCISCO CA 94115 |
Paul L Berns | director | 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
Dan Marquess | officer: Chief Scientific Officer | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
From GuruFocus
By Marketwired • 09-24-2024
By GuruFocus News • 04-22-2025
By GuruFocus News • 05-27-2025
By Marketwired • 07-22-2024
By Marketwired • 03-07-2025
By GlobeNewswire • 03-23-2025
By Marketwired • 05-14-2024
By Marketwired • 03-24-2025
By Marketwired • 08-06-2024
By GuruFocus News • 05-05-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.